Barinthus Biotherapeutics
BRNS
13 hedge funds and large institutions have $21.6M invested in Barinthus Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.05% less ownership
Funds ownership: 27.42% → 27.37% (-0.05%)
3% less capital invested
Capital invested by funds: $22.2M → $21.6M (-$624K)
13% less funds holding
Funds holding: 15 → 13 (-2)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$242K |
| 2 |
Morgan Stanley
New York
|
+$159K |
| 3 |
Renaissance Technologies
New York
|
+$31.7K |
| 4 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
+$15.9K |
| 5 |
Millennium Management
New York
|
+$4.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$401K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$41.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$39.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.81K |
BRNS Hedge Fund Activity: Q1 2023 in Review
13 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q1 2023, worth a combined $21.6M — down 2.8% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BRNS and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Baird Financial Group, adding an estimated $242K. The largest seller was Liontrust Investment Partners, cutting an estimated $401K.
- 13 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q1 2023, down from 15 in Q4 2022.
- Funds reported $21.6M of Barinthus Biotherapeutics stock for Q1 2023, down 2.8% quarter-over-quarter.
- 1 fund opened new Barinthus Biotherapeutics positions in Q1 2023 and 3 closed out, a net change of -2 holders.
- The largest Barinthus Biotherapeutics buyer in Q1 2023 was Baird Financial Group, an estimated $242K added.
- The largest Barinthus Biotherapeutics seller in Q1 2023 was Liontrust Investment Partners, an estimated $401K sold.
Based on aggregated 13F filings for Q1 2023.